<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118505</url>
  </required_header>
  <id_info>
    <org_study_id>P16-03</org_study_id>
    <nct_id>NCT03118505</nct_id>
  </id_info>
  <brief_title>A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions</brief_title>
  <official_title>A Prospective, Randomized, Multi-Center, Open-Label Pilot Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain safety and effectiveness data on the investigational&#xD;
      device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use&#xD;
      in this indication. The study information may be used for a potential pivotal study design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological Fusion Success</measure>
    <time_frame>12 months</time_frame>
    <description>Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:&#xD;
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT);&#xD;
No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and&#xD;
Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Overall success is defined as the participant who meet the following five criteria:&#xD;
Radiographic success, defined as radiological fusion success in the posterolateral space;&#xD;
Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline;&#xD;
Neurological success, defined as maintenance or improvement in neurological status;&#xD;
No SAE related to the PLF grafting material or posterior fixation; and&#xD;
No secondary surgeries classified as a &quot;failure.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>The self-administered Oswestry Disability Index (ODI) Questionnaire (Version 2.1) will be used to assess patient pain and ability to function. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>ODI success is defined as at least a 15-point improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological success rate at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Overall neurological success is defined as maintenance or improvement in four key neurological assessments: motor function, sensory function, reflexes, and straight leg raise. In order to be considered a success, each element in the motor, sensory, reflexes, and straight leg raise examinations must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back pain score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate back pain. The back pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back pain success at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Back pain success is defined as at least 30% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg pain score at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate leg pain. The leg pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg pain success at 12 and 24 months</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Leg pain success is defined as at least 30% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological fusion success rate at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:&#xD;
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT);&#xD;
No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and&#xD;
Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs related to the PLF grafting material or posterior fixation up to 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>A summary of AEs related to the PLF grafting material or posterior fixation up to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>A summary of secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Multi-Level Degenerative Lumbosacral Spinal Conditions</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infuse Bone Graft</intervention_name>
    <description>Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic DBM</intervention_name>
    <description>Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Degenerative lumbar spine condition:&#xD;
&#xD;
               1. Requiring a PLF procedure using a bilateral metallic screw and rod system in 2-4&#xD;
                  consecutive levels from L2-S1; and&#xD;
&#xD;
               2. Diagnosed with: instability (up to and including Grade 2 spondylolisthesis,&#xD;
                  retrolisthesis, or lateral listhesis), stenosis with documented pre-operative&#xD;
                  instability, and/or recurrent disc herniation, any of which may have possible&#xD;
                  concomitant lumbar degenerative deformity (Cobb angle ≤ 30 degrees).&#xD;
&#xD;
          2. Preoperative ODI score ≥40.&#xD;
&#xD;
          3. Preoperative pain score of ≥8 (out of 20) on the Preoperative Leg Pain Questionnaire.&#xD;
&#xD;
          4. Most inferior treated spinal level is able to accommodate an interbody fusion device.&#xD;
&#xD;
          5. ≥21 years of age at the time of signing the informed consent.&#xD;
&#xD;
          6. Failed ≥6 months non-operative treatment (e.g., bed rest, physical therapy,&#xD;
             medications, spinal injections, manipulation, and/or TENS).&#xD;
&#xD;
          7. Is willing and able to comply with the study plan and able to understand and sign the&#xD;
             Subject Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior spinal fusion surgical procedure at the involved or adjacent spinal levels.&#xD;
             (Prior non-fusion surgery at the target levels, including discectomy and/or&#xD;
             single-level foraminotomy or laminectomy, is allowed.)&#xD;
&#xD;
          2. Prior lumbar disc arthroplasty.&#xD;
&#xD;
          3. Significant lumbar instability, defined as sagittal listhesis &gt;Grade 2 at any involved&#xD;
             level using Meyerding's Classification or lateral listhesis &gt;25% lateral translation&#xD;
             at any involved level.&#xD;
&#xD;
          4. Planned use of an internal or external bone growth stimulator.&#xD;
&#xD;
          5. Lumbar scoliosis &gt;30 degrees.&#xD;
&#xD;
          6. Osteoporosis to a degree that spinal instrumentation is contraindicated or a history&#xD;
             of atraumatic vertebral fracture.&#xD;
&#xD;
          7. Morbidly obese, as defined by a Body Mass Index (BMI) &gt;40.&#xD;
&#xD;
          8. Presence of active malignancy or prior history of malignancy.&#xD;
&#xD;
          9. Overt or active bacterial infection, either local or systemic.&#xD;
&#xD;
         10. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic,&#xD;
             immunostimulating, or immunosuppressive agents within 30 days prior to implantation of&#xD;
             the assigned treatment.&#xD;
&#xD;
         11. Comorbidities precluding subject from being a surgical candidate.&#xD;
&#xD;
         12. History of autoimmune disease known to affect bone metabolism or the spine (e.g.,&#xD;
             spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease,&#xD;
             Hashimoto's thyroiditis).&#xD;
&#xD;
         13. History of any endocrine or metabolic disorder known to affect osteogenesis (e.g.,&#xD;
             Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis&#xD;
             imperfecta).&#xD;
&#xD;
         14. History of exposure to any recombinant proteins used for bone formation (i.e., Infuse&#xD;
             Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide&#xD;
             Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft).&#xD;
&#xD;
         15. Hypersensitivity or allergy to any components of the study treatments including, but&#xD;
             not limited to, bone morphogenetic proteins (BMPs); injectable collagen; protein&#xD;
             pharmaceuticals (e.g., monoclonal antibodies or gamma globulins); bovine collagen&#xD;
             products; gentamicin or glycerol (which may be present in trace amounts in the DBM&#xD;
             products); and/or instrumentation materials (titanium, titanium alloy, cobalt chrome,&#xD;
             cobalt chrome alloy, or polyetheretherketone [PEEK]).&#xD;
&#xD;
         16. History of any allergy resulting in anaphylaxis.&#xD;
&#xD;
         17. Is a prisoner.&#xD;
&#xD;
         18. Is mentally incompetent. If questionable, obtain psychiatric consult.&#xD;
&#xD;
         19. Treatment with an investigational therapy (drug, device, and/or biologic) within 30&#xD;
             days prior to implantation surgery, or such treatment is planned during the 24-month&#xD;
             period following implantation of the study treatment.&#xD;
&#xD;
         20. Pregnant or nursing. Females of child-bearing potential must agree not to become&#xD;
             pregnant for one year following surgery.&#xD;
&#xD;
         21. Any condition that would interfere with the subject's ability to comply with study&#xD;
             instructions, might confound the interpretation of the study, or put the subject at&#xD;
             risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chetan Patel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spine Health Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Oien, MBA</last_name>
    <phone>7635268124</phone>
    <email>lauren.k.oien@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Wang-Polagruto</last_name>
      <phone>916-551-3244</phone>
      <email>jfwang@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Kee Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julius Ebinu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronaldo Roberto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spine Colorado</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Steadman Clinic</name>
      <address>
        <city>Vail</city>
        <state>Colorado</state>
        <zip>81657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Spine Health Institute</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Carrigan</last_name>
      <phone>407-303-2367</phone>
      <email>Pamela.Carrigan@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Chetan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation for Orthopedic Research and Education</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Warren, RN, CCRC</last_name>
      <phone>813-978-9700</phone>
      <phone_ext>6766</phone_ext>
      <email>dwarren@foreonline.org</email>
    </contact>
    <investigator>
      <last_name>John Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Vinayek, M.Sc</last_name>
      <phone>317-715-5897</phone>
      <email>svinayek@indianaspinegroup.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Smucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Kraemer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Orthopedics</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Gross</last_name>
      <phone>269-337-4327</phone>
      <email>kathleen.gross@med.wmich.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Wiggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Sloffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Ellwitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Orthopedics</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Craig</last_name>
      <phone>315-464-8618</phone>
      <email>craigt@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>William Lavelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Tallarico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Spine &amp; Scoliosis Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorrie Sipe</last_name>
      <phone>434-924-8775</phone>
      <email>LAG3K@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark E. Shaffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Po Yen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avery L. Buchholz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

